FY2025 EPS Estimates for SiBone Lifted by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share (EPS) estimate for SiBone from ($0.64) to ($0.57) and maintains an "Overweight" rating with a target price of $25.00.
• SiBone reported a quarterly EPS of (0.14), exceeding expectations, with revenues of $48.63 million, which is also above analyst estimates.
• Following a series of insider sales, company insiders now hold 4.00% of SiBone's stock, while institutional investors own 98.11% of the shares.

SiBone (NASDAQ:SIBN - Free Report) - Stock analysts at Cantor Fitzgerald lifted their FY2025 earnings estimates for SiBone in a report issued on Wednesday, August 6th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($0.57) per share for the year, up from their prior forecast of ($0.64). Cantor Fitzgerald currently has a "Overweight" rating and a $25.00 price objective on the stock. The consensus estimate for SiBone's current full-year earnings is ($0.78) per share. Cantor Fitzgerald also issued estimates for SiBone's FY2026 earnings at ($0.32) EPS.

Other equities research analysts have also recently issued research reports about the stock. Truist Financial lifted their price objective on shares of SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Wall Street Zen cut shares of SiBone from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Needham & Company LLC restated a "buy" rating and set a $24.00 price objective on shares of SiBone in a research report on Tuesday, May 6th.

SiBone Price Performance

SIBN traded down $0.11 on Friday, hitting $15.29. 239,646 shares of the company's stock traded hands, compared to its average volume of 430,996. The company's 50 day simple moving average is $17.61 and its 200-day simple moving average is $16.61. The company has a current ratio of 8.38, a quick ratio of 7.00 and a debt-to-equity ratio of 0.21. SiBone has a one year low of $11.70 and a one year high of $20.05. The firm has a market cap of $659.48 million, a price-to-earnings ratio of -27.31 and a beta of 0.91.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. SiBone had a negative return on equity of 14.20% and a negative net margin of 12.83%. The business had revenue of $48.63 million during the quarter, compared to analyst estimates of $48.12 million.

Institutional Investors Weigh In On SiBone

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ANTIPODES PARTNERS Ltd purchased a new stake in SiBone during the 1st quarter valued at $34,000. Virtus Fund Advisers LLC purchased a new position in shares of SiBone during the 4th quarter worth about $40,000. GAMMA Investing LLC grew its holdings in SiBone by 20,352.6% during the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after purchasing an additional 3,867 shares during the last quarter. Virtus Advisers LLC purchased a new stake in SiBone in the 1st quarter worth about $58,000. Finally, KLP Kapitalforvaltning AS bought a new stake in SiBone in the fourth quarter worth about $97,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at SiBone

In other news, CFO Anshul Maheshwari sold 9,585 shares of the company's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $19.76, for a total transaction of $189,399.60. Following the sale, the chief financial officer directly owned 224,507 shares in the company, valued at approximately $4,436,258.32. This represents a 4.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Anthony J. Recupero sold 4,147 shares of the stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $19.56, for a total transaction of $81,115.32. Following the completion of the transaction, the insider directly owned 282,015 shares of the company's stock, valued at approximately $5,516,213.40. The trade was a 1.45% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 65,413 shares of company stock valued at $1,221,524 in the last 90 days. Company insiders own 3.90% of the company's stock.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.